PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma

Authors

  • Eugene T. H. Ek,

    1. Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, 3065, Melbourne, VIC, Australia
    Search for more papers by this author
  • Crispin R. Dass,

    Corresponding author
    1. Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, 3065, Melbourne, VIC, Australia
    • Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, 3065, Melbourne, VIC, Australia. Telephone: +61 3 9288 3954; Fax: +61 3 9416 3610.
    Search for more papers by this author
  • Karla G. Contreras,

    1. Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, 3065, Melbourne, VIC, Australia
    Search for more papers by this author
  • Peter F. M. Choong

    1. Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, 3065, Melbourne, VIC, Australia
    Search for more papers by this author

Abstract

Pigment epithelium-derived factor (PEDF) is one of the most potent inhibitors of angiogenesis, and has recently been demonstrated to have an important multifunctional role in tumor growth, invasion, and metastasis. However, relatively little is known of mechanisms through which PEDF exerts its antitumor activity. Therefore, with the aim of identifying potential functional epitopes specifically against osteosarcoma, we evaluated the bioactivity of four 25-mer synthetic PEDF-derived peptides (termed StVOrth-1, -2 -3, and -4) against a human osteosarcoma cell line, SaOS-2. We found that StVOrth-2 (residues 78–102) predominantly inhibited tumor cell proliferation, while StVOrth-3 (residues 90–114) markedly increased cellular adhesion to collagen type-1, with StVOrth-4 (residues 387–411) demonstrating most significant inhibition of Matrigel invasion. Furthermore, we show that StVOrth-1 (residues 40–64), -2 and -3 induce osteoblastic differentiation, evidenced by increased mineralized nodule formation. Interestingly, although no peptide inhibited angiogenesis in the tube formation assay, StVOrth-3 and -4 markedly suppressed VEGF expression. We further tested the activity of StVOrth-2 and StVOrth-3 in vivo, in an orthotopic model of osteosarcoma and found that both peptides significantly inhibited primary tumor growth and the development of pulmonary metastases. Together these results provide greater insight into the potential mechanisms through which PEDF exerts its antitumor function. Furthermore, this raises the possibility of developing short PEDF fragments as lead compounds for the treatment of osteosarcoma. © 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 25:1671–1680, 2007

Ancillary